Halozyme Therapeutics | HALO - Gross Profit On Sales

Stock Price
81.23
Daily Change
2.81 3.58%
Monthly
8.15%
Yearly
42.26%
Q1 Forecast
69.50

Halozyme Therapeutics reported $281.77M in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 256.99M 13.15M Sep/2025
Agios Pharmaceuticals USD 11.2M 448K Sep/2025
Alnylam Pharmaceuticals USD 1.05B 418.14M Sep/2025
Amarin USD 22.21M 28.15M Sep/2025
Amgen USD 6.48B 307M Sep/2025
Baxter International USD 950M 194M Sep/2025
Cytokinetics USD 1.94M 64.83M Sep/2025
DBV Technologies USD 2.77M 33.21M Sep/2025
Eli Lilly USD 14.59B 1.48B Sep/2025
Halozyme Therapeutics USD 281.77M 2.41M Sep/2025
Ionis Pharmaceuticals USD 155M 293M Sep/2025
MannKind USD 2.1M 216K Sep/2025
Pfizer USD 3.54B 7.61B Sep/2025
United Therapeutics USD 602.1M 108.9M Sep/2025